TY - JOUR
T1 - Evaluation of six commercial and in-house phenotypic tests for detection of AmpC β-lactamases
T2 - is routine detection possible?
AU - Al Mamari, Azza Mohammed Khalifa
AU - Al Jabri, Zaaima
AU - Sami, Hiba
AU - Rizvi, Syed Gauhar A
AU - Chan, Moon Fai
AU - Al Siyabi, Turkiya
AU - Al Muharrmi, Zakariya
AU - Rizvi, Meher
N1 - Funding Information:
This study was funded by an internal grant (#IG20/2021) from the College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
Publisher Copyright:
© 2023 The Author(s).
PY - 2023/9/4
Y1 - 2023/9/4
N2 - BACKGROUND: Phenotypic characterization of the prevalent AmpC β-lactamases in clinical isolates is essential for making informed empirical decisions and critical for strengthening antimicrobial stewardship programmes. This study focused on assessing six assays, two in-house and four commercial phenotypic tests for detection of AmpC, to study the feasibility of making its detection a routine diagnostic microbiology laboratory activity.METHODS: A total of 116 non-duplicate Gram-negative bacteria that were resistant to third-generation cephalosporins and amoxicillin/clavulanic acid, and resistant or susceptible to piperacillin/tazobactam and carbapenems, were screened by cefoxitin discs for AmpC. These isolates were subjected to two in-house (AmpC Tris-EDTA and disc approximation) methods and four commercial tests: D69C AmpC Detection Set; D72C ESBL, AmpC & Carbapenemase Detection Set; combination disc test: ESBL + AmpC Screen Disc Kit; and AmpC MIC Test Strip for confirmation of AmpC production. Ten whole-genome-sequenced AmpC-confirmed Gram-negative isolates were used as positive controls and one as a negative control.RESULTS: The prevalence of AmpC β-lactamases was 16%.
Escherichia coli was a major carrier of plasmid-mediated AmpC (26.5%), followed by
Klebsiella pneumoniae (23.4%). Phenotypically, 61% of AmpCs were detected by Tris-EDTA (accuracy: 73.8%), 76% by disc approximation (accuracy: 89.2%), 75% by the D69C AmpC Detection Set (accuracy: 95.4%), 74% by the D72C AmpC, ESBL & Carbapenemase Detection Set (accuracy: 95.4%), 76% by the combination disc test (accuracy: 95.4%) and 63% by AmpC MIC Test Strip (accuracy: 87.7%). The sensitivity and specificity of D69C were 97.9% and 88.2%, respectively, and 95.9% and 93.8% for the combination disc test, while for the disc approximation test and D72C they were 93.9% and 75%, and 93.9% and 100%, respectively. Screening by cefoxitin screening was less sensitive (75%) and specific (25%). Disc approximation and the combination disc test detect AmpC in Enterobacterales and also
Pseudomonas aeruginosa and
Acinetobacter species.
CONCLUSIONS: We recommend the in-house disc approximation test and the commercial D69C, as well as the combination disc test, as excellent tools for detection of AmpC. The cefoxitin test overcalls AmpC and cannot be considered a good stand-alone test for AmpC detection.
AB - BACKGROUND: Phenotypic characterization of the prevalent AmpC β-lactamases in clinical isolates is essential for making informed empirical decisions and critical for strengthening antimicrobial stewardship programmes. This study focused on assessing six assays, two in-house and four commercial phenotypic tests for detection of AmpC, to study the feasibility of making its detection a routine diagnostic microbiology laboratory activity.METHODS: A total of 116 non-duplicate Gram-negative bacteria that were resistant to third-generation cephalosporins and amoxicillin/clavulanic acid, and resistant or susceptible to piperacillin/tazobactam and carbapenems, were screened by cefoxitin discs for AmpC. These isolates were subjected to two in-house (AmpC Tris-EDTA and disc approximation) methods and four commercial tests: D69C AmpC Detection Set; D72C ESBL, AmpC & Carbapenemase Detection Set; combination disc test: ESBL + AmpC Screen Disc Kit; and AmpC MIC Test Strip for confirmation of AmpC production. Ten whole-genome-sequenced AmpC-confirmed Gram-negative isolates were used as positive controls and one as a negative control.RESULTS: The prevalence of AmpC β-lactamases was 16%.
Escherichia coli was a major carrier of plasmid-mediated AmpC (26.5%), followed by
Klebsiella pneumoniae (23.4%). Phenotypically, 61% of AmpCs were detected by Tris-EDTA (accuracy: 73.8%), 76% by disc approximation (accuracy: 89.2%), 75% by the D69C AmpC Detection Set (accuracy: 95.4%), 74% by the D72C AmpC, ESBL & Carbapenemase Detection Set (accuracy: 95.4%), 76% by the combination disc test (accuracy: 95.4%) and 63% by AmpC MIC Test Strip (accuracy: 87.7%). The sensitivity and specificity of D69C were 97.9% and 88.2%, respectively, and 95.9% and 93.8% for the combination disc test, while for the disc approximation test and D72C they were 93.9% and 75%, and 93.9% and 100%, respectively. Screening by cefoxitin screening was less sensitive (75%) and specific (25%). Disc approximation and the combination disc test detect AmpC in Enterobacterales and also
Pseudomonas aeruginosa and
Acinetobacter species.
CONCLUSIONS: We recommend the in-house disc approximation test and the commercial D69C, as well as the combination disc test, as excellent tools for detection of AmpC. The cefoxitin test overcalls AmpC and cannot be considered a good stand-alone test for AmpC detection.
UR - http://www.scopus.com/inward/record.url?scp=85172177259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85172177259&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/dfbc4689-f3f8-3e1a-bd2c-261f440a0c94/
U2 - 10.1093/jacamr/dlad101
DO - 10.1093/jacamr/dlad101
M3 - Article
C2 - 37670936
SN - 2632-1823
VL - 5
SP - dlad101
JO - JAC-Antimicrobial Resistance
JF - JAC-Antimicrobial Resistance
IS - 5
M1 - dlad101
ER -